Oppenheimer raised the firm’s price target on Tyra Biosciences to $28 from $25 and keeps an Outperform rating on the shares following the company’s Q1 earnings results. The firm noted that it has recently noticed an uptick in investor interest in the story, which it feels “isn’t surprising as we approach initial data from SURF301 later this year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Biosciences sees cash, equivalents sufficient to execute plan through 2026
- Tyra Biosciences reports Q1 EPS (35c), consensus (45c)
- Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
- Tyra Bioscience Expands Board with Two New Appointments
- Tyra Bioscience Gains Pediatric Disease Designation for Achondroplasia Drug Amid FDA Voucher Uncertainty